MOLN.SW

Molecular Partners AG

MOLN.SW, Switzerland

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

https://www.molecularpartners.com

Stock Price

CHF0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MOLN.SW
stock
MOLN.SW

Molecular Partners AG (VTX:MOLN) is definitely on the radar of hedge funds investors who own 50% of the company Yahoo Finance

Read more →
MOLN.SW
stock
MOLN.SW

South Dakota’s Northwest Region shines at the 20x High School Showcase Rodeo. Tri-State Livestock News

Read more →

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

$

Analyst Picks

Strong Buy

0

Buy

1

Hold

1

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.29

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-12.39 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-10.55 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.17

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Molecular Partners AG

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.31

Latest Release

Date

2025-09-30

EPS Actual

-0.32

EPS Estimate

-0.39

EPS Difference

0.07

Surprise Percent

17.9487%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(3)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

CHF 0

Cost Of Revenue

CHF 0

Gross Profit

CHF 0

Operating Expenses

CHF 0

Operating Income

CHF 0

Interest Expense

CHF 0

Pretax Income

CHF 0

Net Income

CHF 0

Income Tax Expense

CHF 0

EBITDA

CHF 0

Total Other Income Expense Net

CHF 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

CHF 0

Short Term Investments

CHF 0

Receivables

CHF 0

Inventories

CHF 0

Total Current Assets

CHF 0

Property Plant Equipment

CHF 0

Total Assets

CHF 0

Payables

CHF 0

Short Term Debt

CHF 0

Long Term Debt

CHF 0

Total Liabilities

CHF 0

Equity

CHF 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

CHF 0

Depreciation

CHF 0

Change In Working Capital

CHF 0

Cash From Operations

CHF 0

Capital Expenditures

CHF 0

Cash From Investing

CHF 0

Cash From Financing

CHF 0

Net Change In Cash

CHF 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.